Replicable generation of rhesus macaque iPSCs for in vitro modeling of genetic frontotemporal dementia

This study establishes a reproducible, ISSCR-compliant protocol for generating and characterizing rhesus macaque induced pluripotent stem cells (RhiPSCs) from MAPT R406W mutation carriers, providing a critical resource for cross-species in vitro modeling of genetic frontotemporal dementia.

The Gist

Imagine you are trying to understand a very complex, broken machine that causes a specific type of memory loss called Frontotemporal Dementia (FTD). For a long time, scientists have only been able to study this machine using human parts (cells) or by building a very rough, simplified model. But to really fix the machine, you need a model that is almost identical to the real thing, right down to the tiny screws and gears.

This paper is about scientists at the Wisconsin National Primate Research Center successfully building that "perfect model" using rhesus macaques (a type of monkey) that naturally carry the same genetic "glitch" found in humans with this disease.

Here is the story of how they did it, explained simply:

1. The Problem: The Monkey "Blueprints" Were Hard to Copy

Scientists knew they had a family of monkeys with a specific genetic mutation (called MAPT R406W) that causes dementia. They wanted to turn the skin cells from these monkeys into Induced Pluripotent Stem Cells (iPSCs).

Think of iPSCs as a "Master Reset Button" for cells. If you have a specialized cell (like a skin cell), pressing this button turns it back into a blank, clay-like state. From this blank state, you can mold it into any other cell type in the body, like a brain cell, to study the disease in a dish.

However, turning monkey cells into these "Master Reset" cells is notoriously difficult. It's like trying to start a car with a very finicky engine; the old methods often resulted in the engine stalling, the parts breaking, or the car never starting at all.

2. The Journey: Trial and Error

The team tried several different ways to press that "Master Reset Button," and they were honest about what failed:

• The "Virus" Method (Sendai Virus): They tried using a harmless virus to deliver the reset instructions.
  • The Analogy: Imagine trying to mail a letter to a house, but the mailman (the virus) keeps knocking the door down and trashing the living room. The monkey cells got too excited, started multiplying uncontrollably (like weeds), and refused to turn into stem cells. It was a messy failure.
• The "Plasmid" Method (Electroporation): They switched to using tiny, circular pieces of DNA (plasmids) and zapping the cells with electricity to force the DNA inside.
  • The Analogy: This is like using a precise laser to shoot a key into a lock. At first, they were shooting in the dark, using the wrong settings. The cells either didn't get the key, or the laser was too strong and fried them.
  • The Breakthrough: They tested 24 different "laser settings" (electroporation programs). They found that specific settings worked like a charm for different monkeys. They also figured out that the monkeys needed a very specific "diet" (a special nutrient soup called UPPS medium) to stay healthy and not turn into the wrong type of cell.

3. The Result: A Perfect Set of Tools

After many attempts, they successfully created 8 new stem cell lines from 4 different monkeys (2 with the disease mutation and 2 without).

• Quality Control: They didn't just make them; they put them through the "drill." They checked the DNA, made sure they weren't contaminated with germs, and even injected some into mice to prove they could turn into any tissue (skin, muscle, nerve) just like a real stem cell should.
• The "Feeder" Secret: They found that these monkey stem cells were picky eaters. They wouldn't grow well on a plain plate; they needed to sit on a bed of mouse cells (called MEFs) to feel safe and grow properly. It's like a baby bird that needs a nest to feel secure before it can learn to fly.

4. Why This Matters: The "Bridge" to Cures

Why go through all this trouble?

• The Bridge: Humans and monkeys are very different. Drugs that work in a human dish often fail in a monkey, and vice versa. These new monkey stem cells are the perfect bridge. They are genetically close enough to humans to be relevant, but they are monkeys, so they behave more like the actual animal we want to test drugs on.
• Testing the Fix: Now, scientists can take these cells, turn them into brain cells, and watch how the "glitch" (the MAPT mutation) breaks the brain. They can then test thousands of potential medicines in a dish to see which ones fix the problem before they ever risk testing on a live monkey or a human.
• Saving Lives: Because these cells are so reliable, scientists can test more drugs faster and with more confidence. This means fewer monkeys need to be used in risky experiments, and we might find a cure for dementia sooner.

In a Nutshell

The scientists figured out the secret recipe to turn monkey skin cells into "blank slate" stem cells. They learned that you need the right electrical zap, the right food, and a cozy nest to make it work. Now, they have a reliable, high-quality toolkit to study dementia and test new cures, acting as a crucial stepping stone between human lab dishes and real-world animal trials.

Technical Summary

1. Problem Statement

Frontotemporal dementia (FTD) linked to the MAPT R406W mutation is a severe neurodegenerative disorder. While human induced pluripotent stem cells (hiPSCs) from carriers exist, they lack the physiological complexity of non-human primate (NHP) models. Rhesus macaques at the Wisconsin National Primate Research Center (WNPRC) naturally carry the same MAPT R406W mutation, offering a unique cross-species model for studying tauopathy.

However, generating and maintaining rhesus iPSCs (RhiPSCs) has historically been inefficient and less reproducible than human protocols. Existing literature often lacks:

• Standardized reprogramming methods for rhesus fibroblasts.
• Robust long-term culture conditions that maintain genetic stability.
• Adherence to International Society for Stem Cell Research (ISSCR) reporting standards (e.g., authentication, cryopreservation, viral screening).
• Detailed reporting of failed trials, which hinders the optimization of protocols for NHPs.

2. Methodology

The study employed a stepwise approach to optimize the derivation, reprogramming, and maintenance of RhiPSCs from four donor rhesus macaques (two MAPT Wild Type [WT] and two MAPT R406W).

A. Fibroblast Derivation

• Source: Skin punch biopsies (6mm) from WT and R406W monkeys.
• Optimization: Compared "manual processing only" vs. "manual + overnight enzymatic digestion" (Collagenase I/DNase I).
• Finding: Enzymatic digestion significantly reduced propagation time (5.3 days vs. 19 days) and yielded low-passage fibroblasts. Notably, R406W fibroblasts became senescent/morphologically abnormal after passage 3–4, necessitating the use of low-passage cells (≤P2) for reprogramming.

B. Reprogramming Strategies
Two delivery methods were evaluated for introducing reprogramming factors (OCT3/4, SOX2, KLF4, c-MYC, and others):

1. Sendai Virus (CytoTune™-iPS 2.0): Three trials were conducted. All failed to produce stable, clonal lines. Issues included excessive fibroblast proliferation (likely due to c-Myc overexpression) and an inability to maintain stemness after initial colony appearance.
2. Non-Integrating Episomal Plasmids (oriP/EBNA1): Twelve trials were conducted using the Neon Transfection System.
   • Variables Optimized: Electroporation programs (24 Neon programs tested), plasmid combinations (including miR-302/367 and EBNA1 mRNA), plating density, and culture media.
   • Key Optimization: Systematic screening of electroporation programs using eGFP uptake and cell survival assays identified optimal programs (#5, #14, #15, #16, #20, #23, #24) specific to different fibroblast lines.

C. Culture Conditions

• Media: Compared Essential 12 + IWR1 (E12+IWR1) vs. Universal Primate Pluripotency Stem Cell (UPPS) medium. E12+IWR1 caused cytogenetic abnormalities; UPPS supported long-term stability.
• Matrix: Compared Mouse Embryonic Fibroblasts (MEFs), Matrigel, and Vitronectin. MEFs combined with UPPS medium yielded the highest cloning efficiency and colony compactness.
• Supplements: Tested Y-27632 and CEPT (chroman 1, emricasan, polyamines, trans-ISRIB) to aid single-cell survival.

D. Characterization (ISSCR Standards)
Eight clonal lines (two per donor) were fully characterized, including:

• Morphology and Alkaline Phosphatase staining.
• Gene expression (RT-PCR) and protein expression (Immunocytochemistry/Flow Cytometry) of pluripotency markers (OCT4, SOX2, NANOG).
• Genotyping to confirm MAPT status and loss of episomal plasmids.
• Karyotyping (G-banding).
• Teratoma formation assays in NCG-X mice.
• Authentication (STR analysis) and pathogen screening (Mycoplasma, Herpes B, SIV, etc.).

E. Differentiation
Selected RhiPSC lines were differentiated into Rhesus Neural Progenitor Cells (RhNPCs) using a monolayer protocol over 21 days.

3. Key Results

• Reprogramming Efficiency: Sendai virus reprogramming was unsuccessful for generating stable RhiPSC lines. In contrast, episomal reprogramming successfully generated eight stable RhiPSC lines from four donors (2 WT, 2 R406W).
• Optimal Protocol: The most successful workflow involved:
  • Enzymatic digestion of biopsies to obtain low-passage fibroblasts.
  • Electroporation using specific Neon programs tailored to the cell line.
  • Culture on MEF feeders in UPPS medium.
• Genetic Stability: All eight lines maintained normal karyotypes and pluripotency markers over >30 passages. Crucially, the episomal plasmids were lost by passage 14–18, confirming transgene-free status.
• Differentiation: RhiPSCs successfully differentiated into RhNPCs expressing PAX6 and NESTIN, demonstrating their potential for neural modeling.
• R406W Phenotype: The study confirmed that MAPT R406W fibroblasts exhibit accelerated senescence and morphological abnormalities (multinucleation) at higher passages, a phenotype that must be managed during derivation.

4. Significance and Contributions

• Standardization of NHP iPSCs: This study establishes a replicable, high-efficiency workflow for generating RhiPSCs, addressing the historical lack of standardized protocols for non-human primates.
• ISSCR Compliance: It is one of the few studies to rigorously apply ISSCR reporting standards to NHP iPSCs, including viral screening (specifically for zoonotic Herpes B virus) and full authentication, setting a new benchmark for the field.
• Resource Generation: The creation of eight characterized, transgene-free RhiPSC lines (including four MAPT R406W lines) provides a critical resource for the scientific community.
• Disease Modeling: These cells enable the study of tau-related neurodegeneration in a primate genetic background that is more physiologically relevant to humans than rodent models. They serve as a preclinical platform for testing therapeutics before in vivo trials in valuable rhesus monkeys.
• Methodological Insights: The paper highlights the superiority of episomal plasmids over Sendai virus for this specific application and identifies the specific culture conditions (UPPS + MEFs) required to prevent cytogenetic instability in rhesus cells.

Conclusion

The authors have successfully developed a robust, reproducible method to generate and maintain rhesus macaque iPSCs. By overcoming challenges in fibroblast derivation, reprogramming efficiency, and culture stability, they have created a vital toolkit for modeling genetic frontotemporal dementia. This work bridges the gap between human cell models and in vivo primate studies, accelerating the development of therapies for tauopathies.